Jubilant Biosys Ltd., a subsidiary of Jubilant Life Sciences Ltd., has achieved an early stage milestone under its collaboration with Endo Pharmaceuticals, resulting in the selection of a cancer drug candidate for development. The drug is anticipated to enter trials by late 2012. The companies will continue the collaboration in the development phase.      The multi-target collaboration focuses on differentiated therapies to address the unmet needs of cancer patients. The collaboration has delive...